Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (141-150 of 791) with videos related to

Pageof 80
Sort By:
Leukemia Research|July 4, 2008
Pregnancy in a patient with hypereosinophilic syndromePatricia Ault, Jorge Cortes, Alice Lynn, et al.
Haematologica|March 2, 2011
Mutant BCR-ABL clones in chronic myeloid leukemiaMichael S Mathisen, Hagop M Kantarjian, Jorge Cortes, et al.
Seminars in Hematology|February 13, 2007
New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistanceElias Jabbour, Jorge Cortes, Susan O'Brien, et al.
Seminars in Hematology|November 20, 2013
Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemiaElias Jabbour, Jorge Cortes, Farhad Ravandi, et al.
Expert Opinion on Investigational Drugs|April 23, 2014
Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemiaNaveen Pemmaraju, Hagop Kantarjian, Michael Andreeff, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 6, 2012
Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibodyPaolo Strati, Jorge Cortes, Stefan Faderl, et al.
Cancer|June 19, 2012
Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008Yiming Chen, Hagop Kantarjian, Haijun Wang, et al.
Cancer|February 2, 2010
Optimizing therapy for patients with chronic myelogenous leukemia in chronic phaseHagop M Kantarjian, Jorge Cortes, Paul La Rosée, et al.
Expert Opinion on Pharmacotherapy|March 21, 2012
Treatment options for chronic myeloid leukemiaMaria Florencia Tanaka, Hagop Kantarjian, Jorge Cortes, et al.
Current Opinion in Investigational Drugs (London, England : 2000)|December 15, 2010
Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemiaFabio P S Santos, Hagop Kantarjian, Jorge Cortes, et al.
Pageof 80

Showing results (141-150 of 791) with videos related to

Sort By:
Pageof 80
Leukemia Research|July 4, 2008
Pregnancy in a patient with hypereosinophilic syndromePatricia Ault, Jorge Cortes, Alice Lynn, et al.
Haematologica|March 2, 2011
Mutant BCR-ABL clones in chronic myeloid leukemiaMichael S Mathisen, Hagop M Kantarjian, Jorge Cortes, et al.
Seminars in Hematology|February 13, 2007
New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistanceElias Jabbour, Jorge Cortes, Susan O'Brien, et al.
Seminars in Hematology|November 20, 2013
Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemiaElias Jabbour, Jorge Cortes, Farhad Ravandi, et al.
Expert Opinion on Investigational Drugs|April 23, 2014
Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemiaNaveen Pemmaraju, Hagop Kantarjian, Michael Andreeff, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 6, 2012
Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibodyPaolo Strati, Jorge Cortes, Stefan Faderl, et al.
Cancer|June 19, 2012
Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008Yiming Chen, Hagop Kantarjian, Haijun Wang, et al.
Cancer|February 2, 2010
Optimizing therapy for patients with chronic myelogenous leukemia in chronic phaseHagop M Kantarjian, Jorge Cortes, Paul La Rosée, et al.
Expert Opinion on Pharmacotherapy|March 21, 2012
Treatment options for chronic myeloid leukemiaMaria Florencia Tanaka, Hagop Kantarjian, Jorge Cortes, et al.
Current Opinion in Investigational Drugs (London, England : 2000)|December 15, 2010
Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemiaFabio P S Santos, Hagop Kantarjian, Jorge Cortes, et al.
Pageof 80